MAP2K7 and neoplasm: Small molecule inhibitors targeting MEK (selumetinib) (Gross et al. 2020) and multiple tyrosine kinases (cabozantinib) (Fisher et al. 2021) have demonstrated clinical activity in tumor volume reduction and pain relief in patients with NF1-associated pNF.